MALAT1 and liver cancer: However, this action was fully abrogated in liver cancer stem cell lines transfected with pCMV6-A-GFP-HULC plus pCMV6-A-GFP-MALAT1 plus pFGP-V-RS—TRF2 or pGFP-V-RS-GFP-HULC plus pGFP-V-RS –MALAT1 plus pcDNA-CREPT (30.56%, 33.24% vs 36.7%, respectively, t-test, P < 0.01) (Fig. 8c).